Skip to main content

01.09.2012 | Original Article

Altered IL-10 and TNF-α production in peripheral blood mononuclear cells of systemic lupus erythematosus patients after Toll-like receptor 2, 4, or 9 activation

verfasst von: Jeng-Ting Tsao, Song-Chou Hsieh, Bor-Luen Chiang, Chia-Li Yu, Shih-Chang Lin

Erschienen in: Clinical and Experimental Medicine | Ausgabe 3/2012

Einloggen, um Zugang zu erhalten

Abstract

Toll-like receptor (TLR) activation and cytokines have been linked to the disease flare of systemic lupus erythematosus (SLE), yet the expression profiles of TLRs and cytokines in response to TLR activation in SLE patients remain unclear. In this study, we evaluated the expression levels of IL-10, TNF-α, interferon-γ (IFN-γ), TLR-2, TLR-4, and TLR-9 in peripheral blood mononuclear cells (PBMCs) from SLE patients and normal controls after PBMCs were stimulated with a TLR-2, TLR-4, or TLR-9 agonist. The expression levels in SLE patient group were statistically compared with those in normal control group. It was found in SLE patients that the IL-10 protein production was down-regulated after the activation of TLR-2, TLR-4, or TLR-9 and that the TNF-α protein production was decreased after the activation of TLR-2 or TLR-9, but not TLR-4. However, the transcript levels of IL-10 and TNF-α as well as the protein and transcript levels of IFN-γ were comparable between SLE and normal control groups. In addition, the TLR-2 transcript levels seem to be diminished after the activation of TLR-2, TLR-4, or TLR-9, but TLR-4 and TLR-9 transcript levels were not altered. The results indicate that the cytokine production from PBMCs in response to TLR activation is dysregulated in SLE patients, supporting the possibility that TLR activation may influence lupus disease activity through regulating cytokine production.
Literatur
1.
Zurück zum Zitat Kumar H, Kawai T, Akira S (2009) Toll-like receptors and innate immunity. Biochem Biophys Res Commun 388(4):621–625PubMedCrossRef Kumar H, Kawai T, Akira S (2009) Toll-like receptors and innate immunity. Biochem Biophys Res Commun 388(4):621–625PubMedCrossRef
2.
Zurück zum Zitat Manicassamy S, Pulendran B (2009) Modulation of adaptive immunity with Toll-like receptors. Semin Immunol 21(4):185–193PubMedCrossRef Manicassamy S, Pulendran B (2009) Modulation of adaptive immunity with Toll-like receptors. Semin Immunol 21(4):185–193PubMedCrossRef
3.
Zurück zum Zitat McCormack W, Parker AE, O’Neill LA (2009) Toll-like receptors and NOD-like receptors in rheumatic diseases. Arthritis Res Ther 11(5):243PubMedCrossRef McCormack W, Parker AE, O’Neill LA (2009) Toll-like receptors and NOD-like receptors in rheumatic diseases. Arthritis Res Ther 11(5):243PubMedCrossRef
4.
Zurück zum Zitat Iwasaki A, Medzhitov R (2010) Regulation of adaptive immunity by the innate immune system. Science 327(5963):291–295PubMedCrossRef Iwasaki A, Medzhitov R (2010) Regulation of adaptive immunity by the innate immune system. Science 327(5963):291–295PubMedCrossRef
5.
Zurück zum Zitat Avalos AM, Busconi L, Marshak-Rothstein A (2010) Regulation of autoreactive B cell responses to endogenous TLR ligands. Autoimmunity 43(1):76–83PubMedCrossRef Avalos AM, Busconi L, Marshak-Rothstein A (2010) Regulation of autoreactive B cell responses to endogenous TLR ligands. Autoimmunity 43(1):76–83PubMedCrossRef
6.
Zurück zum Zitat Lafyatis R, Marshak-Rothstein A (2007) Toll-like receptors and innate immune responses in systemic lupus erythematosus. Arthritis Res Ther 9(6):222PubMedCrossRef Lafyatis R, Marshak-Rothstein A (2007) Toll-like receptors and innate immune responses in systemic lupus erythematosus. Arthritis Res Ther 9(6):222PubMedCrossRef
7.
Zurück zum Zitat Bouza E, Moya JG, Muñoz P (2001) Infections in systemic lupus erythematosus and rheumatoid arthritis. Infect Dis Clin North Am 15(2):335–361PubMedCrossRef Bouza E, Moya JG, Muñoz P (2001) Infections in systemic lupus erythematosus and rheumatoid arthritis. Infect Dis Clin North Am 15(2):335–361PubMedCrossRef
8.
Zurück zum Zitat Juárez M, Misischia R, Alarcón GS (2003) Infections in systemic connective tissue diseases: systemic lupus erythematosus, scleroderma, and polymyositis/dermatomyositis. Rheum Dis Clin North Am 29(1):163–184PubMedCrossRef Juárez M, Misischia R, Alarcón GS (2003) Infections in systemic connective tissue diseases: systemic lupus erythematosus, scleroderma, and polymyositis/dermatomyositis. Rheum Dis Clin North Am 29(1):163–184PubMedCrossRef
9.
Zurück zum Zitat Yap DY, Lai KN (2010) Cytokines and their roles in the pathogenesis of systemic lupus erythematosus: from basics to recent advances. J Biomed Biotechnol 2010:365083PubMedCrossRef Yap DY, Lai KN (2010) Cytokines and their roles in the pathogenesis of systemic lupus erythematosus: from basics to recent advances. J Biomed Biotechnol 2010:365083PubMedCrossRef
10.
Zurück zum Zitat Llorente L, Richaud-Patin Y (2003) The role of interleukin-10 in systemic lupus erythematosus. J Autoimmun 20(4):287–289PubMedCrossRef Llorente L, Richaud-Patin Y (2003) The role of interleukin-10 in systemic lupus erythematosus. J Autoimmun 20(4):287–289PubMedCrossRef
11.
Zurück zum Zitat Palucka AK, Blanck J-P, Bennett L, Pascual V, Banchereau J (2005) Cross-regulation of TNF and IFN-α in autoimmune diseases. Proc Natl Acad Sci USA 102(9):3372–3377PubMedCrossRef Palucka AK, Blanck J-P, Bennett L, Pascual V, Banchereau J (2005) Cross-regulation of TNF and IFN-α in autoimmune diseases. Proc Natl Acad Sci USA 102(9):3372–3377PubMedCrossRef
12.
Zurück zum Zitat Morimoto S, Tokano Y, Nakano S, Watanabe T, Tamayama Y, Mitsuo A et al (2009) Chemoattractant mechanism of Th1 cells in class III and IV lupus nephritis. Autoimmunity 42(2):143–149PubMedCrossRef Morimoto S, Tokano Y, Nakano S, Watanabe T, Tamayama Y, Mitsuo A et al (2009) Chemoattractant mechanism of Th1 cells in class III and IV lupus nephritis. Autoimmunity 42(2):143–149PubMedCrossRef
13.
Zurück zum Zitat Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF et al (1982) The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 25(11):1271–1277PubMedCrossRef Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF et al (1982) The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 25(11):1271–1277PubMedCrossRef
14.
Zurück zum Zitat Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH (1992) Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum 35(6):630–640PubMedCrossRef Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH (1992) Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum 35(6):630–640PubMedCrossRef
15.
Zurück zum Zitat Roda JM, Parihar R, Carson WE 3rd (2005) CpG-containing oligodeoxynucleotides act through TLR9 to enhance the NK cell cytokine response to antibody-coated tumor cells. J Immunol 175(3):1619–1627PubMed Roda JM, Parihar R, Carson WE 3rd (2005) CpG-containing oligodeoxynucleotides act through TLR9 to enhance the NK cell cytokine response to antibody-coated tumor cells. J Immunol 175(3):1619–1627PubMed
16.
Zurück zum Zitat Ozato K, Tsujimura H, Tamura T (2002) Toll-like receptor signaling and regulation of cytokine gene expression in the immune system. Biotechniques Suppl:66–68, 70, 72 passim Ozato K, Tsujimura H, Tamura T (2002) Toll-like receptor signaling and regulation of cytokine gene expression in the immune system. Biotechniques Suppl:66–68, 70, 72 passim
17.
18.
Zurück zum Zitat Migita K, Miyashita T, Maeda Y, Nakamura M, Yatsuhashi H, Kimura H et al (2007) Toll-like receptor expression in lupus peripheral blood mononuclear cells. J Rheumatol 34(3):493–500PubMed Migita K, Miyashita T, Maeda Y, Nakamura M, Yatsuhashi H, Kimura H et al (2007) Toll-like receptor expression in lupus peripheral blood mononuclear cells. J Rheumatol 34(3):493–500PubMed
19.
Zurück zum Zitat Komatsuda A, Wakui H, Iwamoto K, Ozawa M, Togashi M, Masai R et al (2008) Up-regulated expression of Toll-like receptors mRNAs in peripheral blood mononuclear cells from patients with systemic lupus erythematosus. Clin Exp Immunol 152(3):482–487PubMedCrossRef Komatsuda A, Wakui H, Iwamoto K, Ozawa M, Togashi M, Masai R et al (2008) Up-regulated expression of Toll-like receptors mRNAs in peripheral blood mononuclear cells from patients with systemic lupus erythematosus. Clin Exp Immunol 152(3):482–487PubMedCrossRef
20.
Zurück zum Zitat Marshak-Rothstein A (2006) Toll-like receptors in systemic autoimmune disease. Nat Rev Immunol 6(11):823–835PubMedCrossRef Marshak-Rothstein A (2006) Toll-like receptors in systemic autoimmune disease. Nat Rev Immunol 6(11):823–835PubMedCrossRef
Metadaten
Titel
Altered IL-10 and TNF-α production in peripheral blood mononuclear cells of systemic lupus erythematosus patients after Toll-like receptor 2, 4, or 9 activation
verfasst von
Jeng-Ting Tsao
Song-Chou Hsieh
Bor-Luen Chiang
Chia-Li Yu
Shih-Chang Lin
Publikationsdatum
01.09.2012
Verlag
Springer Milan
Erschienen in
Clinical and Experimental Medicine / Ausgabe 3/2012
Print ISSN: 1591-8890
Elektronische ISSN: 1591-9528
DOI
https://doi.org/10.1007/s10238-011-0161-6

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

So sicher sind Tattoos: Neue Daten zur Risikobewertung

22.05.2024 Melanom Nachrichten

Das größte medizinische Problem bei Tattoos bleiben allergische Reaktionen. Melanome werden dadurch offensichtlich nicht gefördert, die Farbpigmente könnten aber andere Tumoren begünstigen.

CAR-M-Zellen: Warten auf das große Fressen

22.05.2024 Onkologische Immuntherapie Nachrichten

Auch myeloide Immunzellen lassen sich mit chimären Antigenrezeptoren gegen Tumoren ausstatten. Solche CAR-Fresszell-Therapien werden jetzt für solide Tumoren entwickelt. Künftig soll dieser Prozess nicht mehr ex vivo, sondern per mRNA im Körper der Betroffenen erfolgen.

Frühzeitige HbA1c-Kontrolle macht sich lebenslang bemerkbar

22.05.2024 Typ-2-Diabetes Nachrichten

Menschen mit Typ-2-Diabetes von Anfang an intensiv BZ-senkend zu behandeln, wirkt sich positiv auf Komplikationen und Mortalität aus – und das offenbar lebenslang, wie eine weitere Nachfolgeuntersuchung der UKPD-Studie nahelegt.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.